| International non-proprietary name |
Trade name |
Type |
Indication first approved |
First EU (US) approval year |
| Muromonab-CD3 |
Orthoclone Okt3 |
Anti-CD3; Murine IgG2a |
Reversal of kidney transplant rejection |
1986* (1986#) |
| Abciximab |
Reopro |
Anti-GPIIb/IIIa; Chimeric IgG1 Fab |
Prevention of blood clots in angioplasty |
1995* (1994) |
| Rituximab |
MabThera, Rituxan |
Anti-CD20; Chimeric IgG1 |
Non-Hodgkin's lymphoma |
1998 (1997) |
| Basiliximab |
Simulect |
Anti-IL2R; Chimeric IgG1 |
Prevention of kidney transplant rejection |
1998 (1998) |
| Daclizumab |
Zenapax |
Anti-IL2R; Humanized IgG1 |
Prevention of kidney transplant rejection |
1999 (1997); # |
| Palivizumab |
Synagis |
Anti-RSV; Humanized IgG1 |
Prevention of respiratory syncytial virus infection |
1999 (1998) |
| Infliximab |
Remicade |
Anti-TNF; Chimeric IgG1 |
Crohn disease |
1999 (1998) |
| Trastuzumab |
Herceptin |
Anti-HER2; Humanized IgG1 |
Breast cancer |
2000 (1998) |
| Gemtuzumab ozogamicin |
Mylotarg |
Anti-CD33; Humanized IgG4 |
Acute myeloid leukemia |
NA (2000#) |
| Alemtuzumab |
MabCampath, Campath-1H |
Anti-CD52; Humanized IgG1 |
Chronic myeloid leukemia |
2001 (2001) |
| Adalimumab |
Humira |
Anti-TNF; Human IgG1 |
Rheumatoid arthritis |
2003 (2002) |
| Tositumomab-I131 |
Bexxar |
Anti-CD20; Murine IgG2a |
Non-Hodgkin lymphoma |
NA (2003) |
| Efalizumab |
Raptiva |
Anti-CD11a; Humanized IgG1 |
Psoriasis |
2004 (2003); # |
| Cetuximab |
Erbitux |
Anti-EGFR; Chimeric IgG1 |
Colorectal cancer |
2004 (2004) |
| Ibritumomab tiuxetan |
Zevalin |
Anti-CD20; Murine IgG1 |
Non-Hodgkin's lymphoma |
2004 (2002) |
| Omalizumab |
Xolair |
Anti-IgE; Humanized IgG1 |
Asthma |
2005 (2003) |
| Bevacizumab |
Avastin |
Anti-VEGF; Humanized IgG1 |
Colorectal cancer |
2005 (2004) |
| Natalizumab |
Tysabri |
Anti-a4 integrin; Humanized IgG4 |
Multiple sclerosis |
2006 (2004) |
| Ranibizumab |
Lucentis |
Anti-VEGF; Humanized IgG1 Fab |
Macular degeneration |
2007 (2006) |
| Panitumumab |
Vectibix |
Anti-EGFR; Human IgG2 |
Colorectal cancer |
2007 (2006) |
| Eculizumab |
Soliris |
Anti-C5; Humanized IgG2/4 |
Paroxysmal nocturnal hemoglobinuria |
2007 (2007) |
| Certolizumab pegol |
Cimzia |
Anti-TNF; Humanized Fab, pegylated |
Crohn disease |
2009 (2008) |
| Golimumab |
Simponi |
Anti-TNF; Human IgG1 |
Rheumatoid and psoriatic arthritis, ankylosing spondylitis |
2009 (2009) |
| Canakinumab |
Ilaris |
Anti-IL1b; Human IgG1 |
Muckle-Wells syndrome |
2009 (2009) |
| Catumaxomab |
Removab |
Anti-EPCAM/CD3;Rat/mouse bispecific mAb |
Malignant ascites |
2009 (NA) |
| Ustekinumab |
Stelara |
Anti-IL12/23; Human IgG1 |
Psoriasis |
2009 (2009) |
| Tocilizumab |
RoActemra, Actemra |
Anti-IL6R; Humanized IgG1 |
Rheumatoid arthritis |
2009 (2010) |
| Ofatumumab |
Arzerra |
Anti-CD20; Human IgG1 |
Chronic lymphocytic leukemia |
2010 (2009) |
| Denosumab |
Prolia |
Anti-RANK-L; Human IgG2 |
Bone Loss |
2010 (2010) |
| Belimumab |
Benlysta |
Anti-BLyS; Human IgG1 |
Systemic lupus erythematosus |
2011 (2011) |
| Raxibacumab |
(Pending) |
Anti-B. anthrasis PA; Human IgG1 |
Anthrax infection |
NA (In review) |
| Ipilimumab |
Yervoy |
Anti-CTLA-4; Human IgG1 |
Metastatic melanoma |
2011 (2011) |
| Brentuximab vedotin |
Adcetris |
Anti-CD30; Chimeric IgG1; immunoconjugate |
Hodgkin lymphoma |
In review (2011) |
| Pertuzumab |
(Pending) |
Anti-HER2; humanized IgG1 |
Breast Cancer |
In review (In review) |
*Country-specific approval; approved under concertation procedure;
#Voluntarily withdrawn from market.
BLyS, B lymphocyte stimulator; C5, complement 5; CD, cluster of differentiation; CTLA-4, cytotoxic T lymphocyte antigen 4; EGFR, epidermal growth factor receptor; EPCAM, epithelial cell adhesion molecule; GP, glycoprotein; IL, interleukin; NA, not approved; PA, protective antigen; RANK-L, receptor activator of NFkb ligand; RSV, respiratory syncytial virus; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.
Source: Janice M. Reichert, Editor-in-Chief, mAbs.
|
